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Abstract: Importance Tumor-treating fields (TTFields) therapy improves both progression-free and over-
all survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients’
health-related quality of life (HRQoL). Objective To examine the association of TTFields therapy with
progression-free survival and HRQoL among patients with glioblastoma. Design, Setting, and Participants
This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolo-
mide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy.
Patients with glioblastoma were randomized 2:1 to combined treatment with TTFields and temozolomide
or temozolomide alone. The study was conducted from July 2009 until November 2014, and patients were
followed up through December 2016. Interventions Temozolomide, 150 to 200 mg/m2/d, was given for
5 days during each 28-day cycle. TTFields were delivered continuously via 4 transducer arrays placed
on the shaved scalp of patients and were connected to a portable medical device. Main Outcomes and
Measures Primary study end point was progression-free survival; HRQoL was a predefined secondary
end point, measured with questionnaires at baseline and every 3 months thereafter. Mean changes from
baseline scores were evaluated, as well as scores over time. Deterioration-free survival and time to de-
terioration were assessed for each of 9 preselected scales and items. Results Of the 695 patients in the
study, 639 (91.9%) completed the baseline HRQoL questionnaire. Of these patients, 437 (68.4%) were
men; mean (SD) age, 54.8 (11.5) years. Health-related quality of life did not differ significantly between
treatment arms except for itchy skin. Deterioration-free survival was significantly longer with TTFields
for global health (4.8 vs 3.3 months; P < .01); physical (5.1 vs 3.7 months; P < .01) and emotional
functioning (5.3 vs 3.9 months; P < .01); pain (5.6 vs 3.6 months; P < .01); and leg weakness (5.6 vs 3.9
months; P < .01), likely related to improved progression-free survival. Time to deterioration, reflecting
the influence of treatment, did not differ significantly except for itchy skin (TTFields worse; 8.2 vs 14.4
months; P < .001) and pain (TTFields improved; 13.4 vs 12.1 months; P < .01). Role, social, and phys-
ical functioning were not affected by TTFields. Conclusions and Relevance The addition of TTFields
to standard treatment with temozolomide for patients with glioblastoma results in improved survival
without a negative influence on HRQoL except for more itchy skin, an expected consequence from the
transducer arrays. Trial Registration clinicaltrials.gov Identifier: NCT00916409.
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IMPORTANCE Tumor-treating fields (TTFields) therapy improves both progression-free and
overall survival in patients with glioblastoma. There is a need to assess the influence of
TTFields on patients’ health-related quality of life (HRQoL).
OBJECTIVE To examine the association of TTFields therapy with progression-free survival and
HRQoL among patients with glioblastoma.
DESIGN, SETTING, AND PARTICIPANTS This secondary analysis of EF-14, a phase 3 randomized
clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients
with glioblastoma after completion of radiochemotherapy. Patients with glioblastomawere
randomized 2:1 to combined treatment with TTFields and temozolomide or temozolomide
alone. The study was conducted from July 2009 until November 2014, and patients were
followed up through December 2016.
INTERVENTIONS Temozolomide, 150 to 200mg/m2/d, was given for 5 days during each
28-day cycle. TTFields were delivered continuously via 4 transducer arrays placed on the
shaved scalp of patients and were connected to a portable medical device.
MAIN OUTCOMES ANDMEASURES Primary study end point was progression-free survival;
HRQoL was a predefined secondary end point, measured with questionnaires at baseline and
every 3months thereafter. Mean changes from baseline scores were evaluated, as well as
scores over time. Deterioration-free survival and time to deterioration were assessed for each
of 9 preselected scales and items.
RESULTS Of the 695 patients in the study, 639 (91.9%) completed the baseline HRQoL
questionnaire. Of these patients, 437 (68.4%)weremen;mean (SD) age, 54.8 (11.5) years.
Health-related quality of life did not differ significantly between treatment arms except for itchy
skin. Deterioration-free survival was significantly longer with TTFields for global health (4.8 vs
3.3months; P < .01); physical (5.1 vs 3.7months; P < .01) and emotional functioning (5.3 vs 3.9
months; P < .01); pain (5.6 vs 3.6months; P < .01); and legweakness (5.6 vs 3.9months;
P < .01), likely related to improved progression-free survival. Time to deterioration, reflecting
the influence of treatment, did not differ significantly except for itchy skin (TTFieldsworse; 8.2
vs 14.4months; P < .001) and pain (TTFields improved; 13.4 vs 12.1months; P < .01). Role, social,
and physical functioningwere not affected by TTFields.
CONCLUSIONSANDRELEVANCE TheadditionofTTFieldstostandardtreatmentwithtemozolomide
for patientswithglioblastoma results in improved survivalwithout anegative influenceonHRQoL
except formore itchy skin, anexpected consequence fromthe transducer arrays.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00916409
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G lioblastomahasapoorprognosis,1,2and,astumorsgrow,patientsoftenexperienceaprogressivedeclineinneurolo-gicfunctionandhealth-relatedqualityof life (HRQoL).3-7
Thecurrentstandardofcare isnotcurativebut results inprolon-
gation of life. However, extension of survival is meaningful
only if patients’ functioning and well-being can be retained or
improved.8-11Therefore, it is importanttodeterminethenetclini-
cal benefit of each new treatment or treatmentmodality intro-
duced;possiblebenefitsofanewtreatment, intermsofprolonged
survival,havetobecarefullyweighedagainstpotentialnegative
effects of the treatment on the patients’ quality of life.
The current standard of care for patients with newly
diagnosed glioblastoma comprises surgical resection to the
extent safely feasible followedby radiotherapywith concomi-
tant and maintenance chemotherapy with temozolomide.12
Tumor-treating fields (TTFields) (Optune;NovocureLtd) is an
antimitotic physical treatment modality13,14 delivered by a
homeusemedical devicewithwired transducer arrays placed
on the patients’ scalp. When added to standardmaintenance
temozolomide chemotherapy, TTFields has been demon-
strated to improve both progression-free survival and overall
survival in a randomized clinical trial (NCT00916409).15
TreatmentwithTTFields involvesthepatientcarryingamo-
bile electrical device for more than 18 hours per day and hav-
ing 4 arrays of transducers continuously fixed to the shaved
scalp. Concerns regarding the influence of wearing the device
on patients’ HRQoL have therefore been raised.16,17 The inci-
dence of adverse events was not increased by the addition of
TTFields to temozolomide therapyexcept for anexpectedmild
tomoderate skin irritationbeneath theelectrodes in52%ofpa-
tients (severe in2%).Herein,wereportonthe influenceof treat-
ment with TTFields on the patients’ HRQoL, which was a pre-
definedsecondaryobjectiveof therandomizedclinical trial.The
present study was conducted from July 2009 until November
2014, and patients were followed up through December 2016.
Methods
Study Population
Patients eligible for this studywere aged 18 years or older, had
newly diagnosed and histologically confirmed supratentorial
glioblastoma (World Health Organization grade IV astrocy-
toma), were progression free after undergoing maximal safe
debulking surgery or biopsy, and had completed standard ra-
diotherapywith concomitant temozolomide.Patientswere re-
quired tohaveaKarnofskyPerformanceStatus scoreof at least
70at thetimeofenrollment,correspondingtoat leastbeingable
toperformself-care.Furtherdetailsonthestudypopulationare
available elsewhere.15 All patients provided written informed
consent, and the study was approved by the institutional re-
viewboardsorethicscommitteesofallparticipatingcentersand
therelevantcompetentauthorities (eAppendix1 inSupplement
1); the participants did not receive financial compensation.
Study Design and Treatment
Thisprospective,multicenter, open-label, randomizedclinical
phase3trial recruited695patientsat90medicalcenters inNorth
America,Europe, theRepublicofKorea,andIsrael.Thetrialpro-
tocol is available inSupplement2.The trialwasdesignedto test
the efficacy of TTFields in combinationwith the best standard
of care in the treatment of newly diagnosed glioblastoma (ie,
radiotherapy with concomitant and adjuvant temozolomide).
Theprimaryendpointwasprogression-freesurvival,withover-
all survival as a powered secondary end point. Health-related
qualityof lifewasasecondaryendpoint.Patientswhowerepro-
gression freeafter completionof radiochemotherapywere ran-
domizedwithin4 to7weeksat a ratioof 2:1 to receive standard
maintenancetemozolomidechemotherapy(150-200mg/m2for
5 days every 28 days for 6 cycles) with or without the addition
ofTTFields. If toleratedwell, TTField therapywas tobecontin-
ued until the second progression or up to 2 years.
Patients in the TTFields plus temozolomide group
received continuous TTFields combined with maintenance
temozolomide.TTFieldsweredelivered throughaportablede-
vice in an outpatient setting. Patients receiving TTFields had
4 transducer arrayswith9 insulatedelectrodes eachplacedon
the shaved scalp and connected to a portable device set to
generate 200-kHz electric fields within the brain. Although
uninterrupted treatmentwas recommended, thepatient could
take short breaks if needed; patients were advised to con-
tinue treatment for at least 18 hours a day.More details on the
study design and treatment are published elsewhere.15
HRQoL Assessment
The evaluation of HRQoL was performed using the validated
European Organisation for Research and Treatment of Can-
cer (EORTC)quality-of-lifequestionnaire (QLQ-C30) andbrain
module (QLQ-BN20).18-20 Questionnaireswere completed on
paper at baseline (prior to randomization) and subsequently
every3months forup to 12months.Ninescalesand itemswere
preselected as important basedon relevance for patientswith
glioblastoma and hypothesized effects of the TTFields deliv-
ery device onpatients’HRQoL: global health status; physical,
cognitive, role, social, and emotional functioning; itchy skin;
pain; andweakness of legs.Wehypothesized that anyburden
of carrying thedevice (onphysical functioning and itchy skin)
or detriment to social and role functioning due to the visibil-
ity of the therapymaybebalancedbypatients’ feeling ofwell-
being (global health status and emotional functioning)
Key Points
Question What is the influence of adding tumor-treating fields to
the standard treatment on health-related quality of life in patients
with glioblastoma?
Findings In this secondary analysis of the EF-14 randomized
clinical trial, the addition of tumor-treating fields did not negatively
influence health-related quality of life except for itchy skin, an
expected consequence from the transducer arrays.
Meaning Tumor-treating field therapy has previously been shown
to prolong both progression-free and overall survival. When
considering the net clinical benefit, improved survival without a
negative influence on health-related quality of life supports the
addition of tumor-treating fields to standard treatment in patients
with glioblastoma.
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related to activeparticipationof both thepatient and the care-
giver in the fight against cancer and increasing patient em-
powerment. Moreover, we hypothesized that treatment with
TTFields would not have an influence on cognitive function-
ing, pain, and weakness of legs.
Statistical Analysis
Calculation of HRQoL Scores
The itemsonbothquestionnaireswerescaledandscoredusing
therecommendedEORTCprocedures.21Rawscoreswere trans-
formed to a linear scale ranging from 0 to 100, with a higher
score representing ahigher level of functioningorhigher level
of symptoms. The results of this study are presented in accor-
dance with guidelines for reporting HRQoL in cancer clinical
trials andmethods.22-24 Differences of at least 10 points (on a
0-100 scale) were classified as theminimum clinicallymean-
ingful change in any HRQoL scale/item.24
Descriptive Statistics
Descriptive statisticswereused to reportHRQoLscores aswell
as the sociodemographic and clinical variables for the popu-
lationofpatientswhocompletedat least 1HRQoLscaleatbase-
line separately for both treatment groups. Means and SDs or
medians and rangeswere calculated for continuous variables
dependingon thedistributionof thevariable.Frequencies and
percentages were calculated for nominal variables. Differ-
ences between arms were tested using a 2-sided χ2 test or an
independent 2-tailed, unpaired t test orMann-Whitney test at
an α value of .05 for each variable.
Adherence to HRQoL assessments was calculated as the
number of forms receiveddividedby thenumber of forms ex-
pected at every assessment. Patients who completed the as-
sessments at the time of progression were included in this
analysis.
HRQoL Scores Over Time
Mean HRQoL scores over time were calculated as well as the
mean changes from baseline. A stable HRQoL score was de-
fined as a change of less than 10 points, and a change of 10 or
morepoints indicatedadeteriorationor improvementdepend-
ing on the scale or item.Mean change from baselinewas plot-
ted to evaluate the longitudinal course of patients' experience
of disease and treatment, and a linearmixed-model repeated-
measures analysis was used to estimate the treatment effect
over time. A sensitivity analysis of complete cases usingmul-
tiple imputationswith a predictivemeanmatching regression
model was used to check the robustness of the treatment ef-
fect over time. An additional sensitivity analysis used a re-
peated-measures model that assumes there is random varia-
tion among participants that is related to the time of dropout.
Stable or Improved HRQoL During the Progression-Free Period
The percentage of patients with stable (<10-point change) or
improved (≥10-point change) HRQoL during the progression-
freeperiod, thus excluding theHRQoLassessment at progres-
sion,wasdeterminedseparately for both treatment arms.This
calculation was based on the total number of patients with a
valid baseline HRQoL assessment and at least 1 additional
follow-up assessment. Moreover, the area under the curve of
stable or improved HRQoL for the entire duration of stability
or improvement was determined, and differences between
armswere assessedwith the trapezoidalmethod (eAppendix
2 in Supplement 1).
Deterioration-Free Survival and Time to Deterioration
Deterioration-free survival was defined as the time to a
greater than 10-point deterioration in scores from baseline
without a subsequent 10-point or more improvement in
scores compared with baseline, progressive disease, or
death in the absence of a previous definitive deterioration
before the next assessment. Disease progression was
included as a surrogate measure. Data were censored at the
last HRQoL assessment date for patients with a change of
less than 10 points, patients who did not progress, or
patients who died after 9 weeks since the last assessment.
Data for patients with missing baseline scores were not
included, and patients missing all postbaseline HRQoL
assessments were censored at randomization. Time to dete-
rioration (TTD) was defined similarly to deterioration-free
survival, with the exception that progressive disease was
excluded as an event (ie, nonmissing HRQoL data beyond
progression were included). Kaplan-Meier methodology
was used to estimate deterioration-free survival and TTD
distributions and median times, and 95% CIs were com-
puted using the Greenwood formula. The difference
between treatment arms was compared using a 2-sided
stratified log-rank test. Hazard ratios were estimated using a
stratified (for extent of resection andMGMT status) Cox pro-
portional hazards regression model.
SAS, version 9.4 (SAS Institute)was used for all statistical
analyses, and comparisonsbetweengroupswerebasedon the
intent-to-treat principle. P values <.05were considered to be
statistically significant. TheHochberg procedurewas used to
adjust for the multiplicity of treatment comparisons in the
preselected HRQoL scales analyses.
Results
Patients
A total of 695 patients were randomly assigned in a 2:1 ratio
to TTFields plus temozolomide (n = 466) or temozolomide
alone (n = 229). A total of 639 (91.9%) patients completed at
least 1 HRQoL scale at baseline: 437 (93.8%) of those in the
TTFields plus temozolomide armand202 (88.2%) patients in
temozolomide-alonearm (Figure 1). Thebaselinedemograph-
ics of the patients who provided HRQoL data were compa-
rable to those of the intention-to-treat population15 andwere
well balanced between treatment arms in this subpopulation
(Table 1).
HRQoL Completion Rates and Baseline Scores
Adherence to HRQoL assessments decreased from 91.9% at
baseline to 65.8% (431 of 655 patients alive) at 3 months and
dropped to 41.7% (197 of 473 patients alive) at 12 months of
follow-up (Figure 1).MeanandmedianbaselineHRQoLscores
TreatmentWith Tumor-Treating Fields in Patients With Glioblastoma Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology April 2018 Volume 4, Number 4 497
© 2018 American Medical Association. All rights reserved.
Downloaded from jamanetwork.com by UZH Hauptbibliothek / Zentralbibliothek Zuerich user on 02/11/2019
were comparable between arms for all preselected scales/
items (eTable 1 in Supplement 1), as well as the exploratory
scalesand items.ReferencevaluesofHRQoLscoresofahealthy
generalpopulation25wereavailable for 7of9predefinedscales
and items (except itchy skin and weakness of legs). Patients
with glioblastoma after completion of radiochemotherapy
showed clinically relevant worse functioning or more symp-
toms compared with the general population on all scales
except pain, which was similar.25
Mean Changes in HRQoL FromBaseline
and the Repeated-MeasuresMixed-EffectModel
Mean changes in HRQoL over time for the global health
status is presented in Figure 2A and for all 9 predefined
HRQoL scales in the eFigure in Supplement 1. Throughout the
12-monthassessmentperiod,meanchanges frombaselinewere
stable (<10-point change from baseline) for all 9 predefined
HRQoL scales in both treatment arms (eFigure in Supplement
1) with the exception of itchy skin (Figure 2B). For itchy skin,
a clinically relevantdeterioration (ie, an increase in itchy skin)
compared with baseline was seen at the month 3 evaluation
in the TTFields plus temozolomide arm (mean [SD] increase,
10.4 [30.1] points vs an improvementof 2.3 [24.4]points in the
temozolomide arm). Fordifferencesbetween treatment arms,
patients treatedwithTTFieldsplus temozolomidehad signifi-
cantly and clinically relevant worse itchy skin at 3, 6, and 9
months than patients treated with temozolomide alone, but
not at 12 months (mean [SD] increase of 10.4 [30.1] in the
TTFields plus temozolomide arm vs a decrease of 2.3 [24.4]
in the temozolomide-alonearm,P = .005; increaseof8.1 [31.6]
in the TTFields plus temozolomide arm vs a decrease of 4.2
[31.4] in the temozolomide-alonearm,P = .008; increaseof5.3
[28.0] in the TTFields plus temozolomide arm vs a decrease
of 5.2 [29.6] in the temozolomide-alone arm, P = .04;
increase of 4.6 [32.8] in the TTFields plus temozolomide arm
vs a decrease of 1.9 [36.9] in the temozolomide-alone arm,
P = .66, respectively). For all other scales, there were no
statistically significant or clinically relevant differences
between treatment arms.
The repeated-measures mixed-effect model supported
this finding, with no statistically significant difference
between treatment arms in HRQoL scores over time in any
predefined scale or itemexcept for itchy skin (P < .001),which
was worse in the TTFields plus temozolomide arm (eTable 2
in Supplement 1). The sensitivity analyses showed that the
results of the linear mixed model were robust.
Stable or Improved HRQoL During Progression-Free Time
Compared with baseline, more patients in the TTFields plus
temozolomide arm compared with the temozolomide-alone
arm reported stable or improved scores for global health sta-
tus (53.5% vs 38.0%, respectively, P = .001), physical func-
tioning (54.0% vs 37.0%, respectively; P = .001), pain (56.8%
vs 35.9%, respectively;P < .001), andweakness of legs (58.7%
vs 42.0%, respectively; P = .001) but not in any of the other
HRQoL scales and items. However, the duration of stable or
improved HRQoLwas shorter in the TTFields plus temozolo-
mide arm, althoughnot significantly different from the temo-
zolomide arm for any of theHRQoL scales and items. Overall,
withacombinationof thesemeasures, theareaunder thecurve
analysis showed no significant differences between treat-
ment arms for any of the HRQoL scales and items, indicating
a similar HRQoL between treatment arms while patients did
not experience tumor progression (Table 2).
Deterioration-Free Survival and TTD
The addition of TTFields to standard temozolomide chemo-
therapyresulted instatistically significant longerdeterioration-
free survival in global health status, physical and emotional
functioning, pain, andweakness of legs (Figure 3AandeTable
2 in Supplement 1); the significant difference remained after
correction for multiple testing. When progression was re-
moved as a deterioration event (TTD), there was no negative
influenceofTTFieldsplus temozolomide treatmentontheTTD
of HRQoL (Figure 3B) except for itchy skin, which was worse
in the TTFields plus temozolomide arm (8.2 vs 14.4months).
In contrast, the addition of TTFields to temozolomide re-
sulted in a statistically significant prolongation until deterio-
ration for pain (13.4 vs 12.1 months, P < .01). There were no
other significantdifferences inTTDbetweenarms (Figure 3B).
Discussion
InourdetailedanalysisofHRQoLduring therapywithTTFields
in addition to temozolomide, no significant difference was
found between the groups in patients’ HRQoL over time
except for the skin reaction. As expected, itchy skin was
Figure 1. CONSORTDiagram
695 Intent-to-treat population
466 TTFields/temozolomide 229 Temozolomide alone
3-Month HRQoL
305 Alive pts (68.2%)
265 Progression-free pts (77.7%)
3-Month HRQoL
126 Alive pts (60.6%)
97 Progression-free pts (78.9%)
6-Month HRQoL
244 Alive pts (58.0%)
172 Progression-free pts (75.1%)
6-Month HRQoL
107 Alive pts (56.0%)
54 Progression-free pts (81.8%)
9-Month HRQoL
156 Alive pts (41.4%)
104 Progression-free pts (72.2%)
9-Month HRQoL
78 Alive pts (47.0%)
41 Progression-free pts (78.9%)
12-Month HRQoL
139 Alive pts (42.3%)
75 Progression-free pts (75.0%)
12-Month HRQoL
58 Alive pts (40.3%)
28 Progression-free pts (80.0%)
437 Baseline HRQoL
(93.8% of pts)
202 Baseline HRQoL
(88.2% of pts)
Data are the number and percentage of patients in the categories (baseline,
alive, and progression-free) who completed the health-related quality-of-life
(HRQoL) questionnaire at the indicated times. pts indicates patients;
TTFields, tumor-treating fields.
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reportedmore frequently inpatients treatedwithTTFieldsbe-
cause of the transducer arrays that have to be placed on the
scalp of thepatient. Consistently, over half of thepatients also
reported skin irritation as an adverse event. We had hypoth-
esized that patients treated with TTFields may have better
HRQoL in some domains as a result of active participation in
Table 1. Baseline Demographic and Disease Characteristics
Characteristic
TTFields Plus
Temozolomide
(n = 437)
Temozolomide
(n = 202)
All Patients
(N = 639) P Value
Age, y
Mean (SD) 54.6 (11.4) 55.2 (11.6) 54.8 (11.5) .50
Median (range) 56.0 (19-83) 57.0 (19-80) 56.0 (19-83)
Sex, No. (%)
Male 297 (68.0) 140 (69.3) 437 (68.4)
.73
Female 140 (32.0) 62 (30.7) 202 (31.6)
Antiepileptic medication at baseline,
No. (%)
174 (39.8) 79 (39.1) 253 (39.6) .87
Corticosteroid therapy at baseline, No. (%) 129 (29.5) 60 (29.7) 189 (29.6) .96
Region, No. (%)
United States 203 (46.5) 97 (48.0) 300 (46.9)
.71
Canada, Europe, Israel, and Korea 234 (53.5) 105 (52.0) 339 (53.1)
Extent of resection, No. (%)
Biopsy 55 (12.6) 24 (11.9) 79 (12.4)
.97Partial resection 149 (34.1) 70 (34.7) 219 (34.3)
Gross total resection 233 (53.3) 108 (53.5) 341 (53.4)
Tumor position, No. (%)a
Corpus callosum 23 (5.3) 12 (5.9) 35 (5.5)
.66
Frontal lobe 177 (40.5) 74 (36.6) 251 (39.3)
Occipital lobe 55 (12.6) 24 (11.9) 79 (12.4)
Parietal lobe 138 (31.6) 78 (38.6) 216 (33.8)
Temporal lobe 179 (41.0) 81 (40.1) 260 (40.7)
Missing 2 (<1) 2 (1.0) 4 (0.6)
Tumor location, No. (%)a
Left 202 (46.2) 84 (41.6) 286 (44.8)
.65
Right 234 (53.5) 116 (57.4) 350 (54.8)
Both 4 (0.9) 2 (1.0) 6 (0.9)
Corpus callosum 14 (3.2) 9 (4.5) 23 (3.6)
Completed radiotherapy, No. (%)
<57 Gy 20 (4.6) 10 (5.0) 30 (4.7)
.38
60 Gy (standard; ±5%) 399 (91.3) 188 (93.1) 587 (91.9)
>63 Gy 15 (3.4) 3 (1.5) 18 (2.8)
Missing 3 (0.7) 1 (0.5) 4 (0.6)
Karnofsky performance score
Median (range) 90 (60-100) 90 (70-100) 90 (60-100) .26
Baseline Mini-Mental State Examination
score available, No. (%)
429 (98.2) 194 (96.0) 623 (97.5)
≤26 81 (18.9) 43 (22.2) 124 (19.9)
.34
27-30 348 (81.1) 151 (77.8) 499 (80.1)
Cycles (months) of treatment with
TTFields
NA NA NA
No. 425
Mean (SD) 12.5 (11.8)
Median (range) 8.3 (0-82)
Cycles of treatment with temozolomide
No. 430 192 622
Mean (SD) 8.9 (8.3) 7.5 (6.2) 8.5 (7.8) .02
Median (range) 6.2 (0-51) 5.5 (0-33) 5.9 (0-51)
Adherence to TTFields therapy b 327 (74.8) NA NA NA
Abbreviations: Gy, gray; NA, not
applicable; TTFields, tumor-treating
fields.
a Multiple locations possible.
bDefined as use of the device 75% or
more of the time during the first 3
months of treatment.
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the fight against cancer and the frequent interactions be-
tween patients and caregivers and device technicians regard-
ing the device. However, on a group level, global health sta-
tus andemotional functioningwerenot significantlydifferent
between treatment arms. Likewise, our hypotheses that the
additionofTTFieldswould result inworse roleandsocial func-
tioning (due to the visibility of the device) and worse physi-
cal functioning were not confirmed. In line with our hypoth-
eses, cognitive functioning, pain, and weakness of legs were
not negatively affected by the addition of TTFields to temo-
zolomide treatment. Most relevant for patients, HRQoL was
maintained (in8of9of thepredefinedscales/items)over time.
Combining the resultsof the survival andHRQoLanalyses sug-
gests that the addition of TTFields to adjuvant temozolomide
is of value to patients with glioblastoma.
Patients who received TTFields had significantly longer
deterioration-free survival compared with those in the
temozolomide-alone arm for global health status (4.8 vs 3.3
months; P < .01), physical (5.1 vs 3.7 months; P < .01) and
emotional functioning (5.3 vs 3.9 months; P < .01), pain (5.6
vs 3.6 months; P < .01), and weakness of legs (5.6 vs 3.9
months; P < .01). For the other scales and items, there was
no significant difference in deterioration-free survival
between the 2 treatment arms. The prolonged deterioration-
free survival for these scales is explained by the extended
progression-free survival for patients in the combined
TTFields plus temozolomide arm, as progressive disease is
included as an event in this analysis. Therefore, TTD analy-
ses, excluding progressive disease as an event, is important
to illustrate the influence of a treatment on HRQoL: TTD was
not significantly different across any HRQoL scale or item in
TTFields-treated patients except for pain and itchy skin,
indicating that treatment with TTFields had an influence
only on the level of pain and itchy skin. In patients treated
with TTFields, TTD was significantly longer for pain (13.4 vs
12.1 months; P < .01) and significantly shorter for itchy skin
(8.2 vs 14.4 months; P < .001). The difference between
deterioration-free survival and TTD indicates the impor-
tance of disease progression (rather than treatment) as a key
event driving HRQoL decline, as suggested by previous
studies.26,27 Moreover, in only 1% of patients, regardless of
treatment arm, was a clinically relevant improvement in
HRQoL seen after initial deterioration, supporting this obser-
vation. Taken together, the results of the deterioration-free
survival and TTD analyses support the results of the longitu-
dinal analysis by showing that the addition of TTFields to
the standard of care did not adversely affect HRQoL. In fact,
the delay in TTD for pain seen in TTFields-treated patients
may reflect a delay in the occurrence of tumor-related head-
aches (although not significant, patients in the TTFields plus
temozolomide arm had a longer TTD compared with
patients in the temozolomide-alone arm for headaches: haz-
ard ratio, 0.77; 95% CI, 0.54-1.10; P = .16). Future studies are
needed to better understand this finding, as the median TTD
values for pain were longer than the median progression-
free survival for both arms.
Limitations
A common problem in many cancer clinical trials, as in this
study, is missing HRQoL data. This absence is especially
apparent during the follow-up period, hampering longitudi-
nal data analysis. Patients with better prognostic factors and
a good treatment response will be overrepresented at later
stages.28,29 However, our mixed-model analyses, account-
ing for missing data, confirmed the results found in the
mean change from baseline analyses. Another limitation of
clinical trials is generalizability of results—patients in clini-
cal trials may not be representative of a general glioblas-
toma population. Patients in this trial were included only if
they successfully completed the combined radiochemo-
therapy. In addition, it may be that not all patients are pre-
pared to accept wearing the TTFields device. Nevertheless,
Figure 2. Changes in Global Health Status and Itchy Skin
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patients participating in this trial were similar with respect
to clinical characteristics to those participating in the
EORTC 26981 study12 comparing radiotherapy alone with
radiotherapy plus temozolomide. Lastly, many factors may
affect HRQoL, such as age, comorbidity, tumor characteris-
tics, previous antitumor treatment (eg, radiation dose), and
supportive treatment. However, it is unlikely that these fac-
tors influenced our conclusion, as the objective of this study
was to compare HRQoL results between 2 treatment arms in
which patients were similar due to randomization.
Table 2. Stable or Improved Health-Related Quality of Life During Progression-Free Time
Characteristic
TTFields Plus
Temozolomide
(n = 361)
Temozolomide
(n = 142) P Value α Value
Pain
Stable/improved from baseline,
No./No. (%)
205/361 (56.8) 51/142 (35.9) <.001 .05
Median duration (95% CI), mo 6.2 (5.9 to 7.0) 6.3 (5.6 to 9.1) .88
Median CFB AUC until last
stable/improved status (95% CI)
0 (0 to 0) 0 (0 to 0) .80
Global health status
Stable/improved from baseline,
No./No. (%)
192/359 (53.5) 53/141 (37.6) .001 .025
Median duration (95% CI), mo 6.3 (5.9 to 7.4) 7.9 (5.9 to 9.8) .24
Median CFB AUC until last
stable/improved status (95% CI)
24.4 (11.9 to 35.0) 65.9 (13.1 to 121.3) .13
Physical functioning
Stable/improved from baseline,
No./No. (%)
195/361 (54.0) 54/142 (38.0) .001 .017
Median duration (95% CI), mo 6.2 (5.9 to 8.2) 9.1 (5.9 to 9.8) .21
Median CFB AUC until last
stable/improved status (95% CI)
0 (0 to 18.7) 0 (0 to 30.0) .53
Weakness of legs
Stable/improved from baseline,
No./No. (%)
206/351 (58.7) 58/138 (42.0) .001 .013
Median duration (95% CI), mo 6.3 (6.0 to 8.3) 9.1 (5.9 to 9.8) .08
Median CFB AUC until last
stable/improved status (95% CI)
0 (0 to 0) 0 (0 to 0) .51
Cognitive functioning
Stable/improved from baseline,
No./No. (%)
181/359 (50.4) 55/142 (38.7) .02 .01
Median duration (95% CI), mo 6.0 (4.9 to 6.5) 6.2 (5.7 to 9.6) .65
Median CFB AUC until last
stable/improved status (95% CI)
26.3 (0 to 48.6) 0 (0 to 93.3) .37
Emotional functioning
Stable/improved from baseline,
No./No. (%)
196/359 (54.6) 62/142 (43.7) .03 .008
Median duration (95% CI), mo 6.3 (6.0 to 8.3) 7.7 (5.8 to 9.4) .38
Median CFB AUC until last
stable/improved status (95% CI)
22.6 (5.8 to 35.0) 25.2 (0 to 54.4) .73
Social functioning
Stable/improved from baseline,
No./No. (%)
173/359 (48.2) 58/142 (40.8) .14 .007
Median duration (95% CI), mo 6.2 (5.9 to 7.1) 6.7 (5.9 to 9.6) .40
Median CFB AUC until last
stable/improved status (95% CI)
16.5 (0 to 47.2) 0 (0 to 54.4) .90
Role functioning
Stable/improved from baseline,
No./No. (%)
173/361 (47.9) 58/141 (41.1) .17 .006
Median duration (95% CI), mo 5.9 (4.4 to 6.3) 7.3 (5.7 to 9.3) .27
Median CFB AUC until last
stable/improved status (95% CI)
0 (0 to 25.0) 46.7 (0 to 75.8) .34
Itchy skin
Stable/improved from baseline,
No./No. (%)
148/349 (42.4) 64/137 (46.7) .39 .0056
Median duration (95% CI), mo 6.0 (4.7 to 6.3) 6.7 (5.6 to 9.4) .37
Median CFB AUC until last
stable/improved status (95% CI)
0 (0 to 0) 0 (−102.2 to 0) .19
Abbreviations: AUC, area under the
curve; CFB, change from baseline;
TTFields, tumor-treating fields.
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Conclusions
Use of TTFields prolongs progression-free and overall sur-
vival in patients with glioblastoma. The addition of this
novel device-delivered treatment neither negatively affects
nor improves functioning and well-being of the patient,
including critical HRQOL issues, such as role, social, and
physical functioning. Patients reported more itchy skin,
which is a direct and expected consequence of the place-
ment of transducer arrays on the patients’ scalp. Consider-
ing the net clinical benefit, our HRQoL data support the
addition of TTFields to standard therapy in patients with
glioblastoma.
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Invited Commentary
Tumor-Treating Fields
Answering the Concern About Quality of Life
LiaM. Halasz, MD; Timur Mitin, MD, PhD
Since the 2005 publication of the randomized European
Organization for Research and Treatment of Cancer/National
Cancer Institute of Cancer trial that established concurrent
radiotherapy (RT) and temo-
zolomide for upfront treat-
mentof glioblastoma (GBM),1
littleprogresshasbeenmade.
Thus, itwas remarkablewhen the interim results for theEF-14
trial were published, documenting a 4.9-month increase in
median overall survival with the addition of tumor-treating
fields (TTFields) to standard therapy with combined RT
and temozolomide.2 These findings were strengthened
by presentation of the mature analysis at the Society for
Neuro-oncology Meeting in 2016, which confirmed that the
median survival improved from 16 months after randomiza-
tion to RT plus temozolomide to 21months with the addition
of TTFields to RT plus temozolomide.3 The survival advan-
tage continued at later times, such as the 2-year survival rate
of 30% vs 42.5% (P = .001).
Since its introduction, many physicians have remained
skeptical about includingTTFields as standardof care,4 inpart
due to thenoveltyof themechanismofaction.Thedevicegen-
erates low-intensity, intermediate-frequency (200kHz) alter-
natingelectric fields that interferewithmitosis anddisrupt the
division of cells. Since its initial use for treatment of GBM,
TTFields is now being tested for other cancer types, includ-
ingmetastatic non–small cell lung cancer,5 and as an alterna-
tive to prophylactic cranial irradiation in small cell lung
cancer (Oregon Health Sciences University/University of
Washington trial, starting accrual in early 2018). Further-
more, physicians andpatients havebeen concernedabout the
quality-of-life implications of wearing a mobile electrical
device with 4 arrays of transducers continuously fixed to a
shaved scalp for at least 18 hours a day. The battery pack for
thedevice is largeandheavyenoughthat it could interferewith
daily activities. Quality of life remains a priority for many of
our patients since clinical trials have shown incremental
improvement in overall survival, but not cure.
An interim analysis of the EF-14 trial focusing on health-
related quality of life (HRQoL), published by Zhu and
colleagues,6 suggested initial improvement in global HRQoL
with TTFields in the first 6 months. Skin toxic effects con-
cerns were higher among patients randomized to the com-
bined TTFields, RT, temozolomide arm. The final analysis of
these data, published by Taphoorn and colleagues7 in this
issue of JAMAOncology, presents important data for evaluat-
ing the overall effect of TTFields on our patients. In contrast
to the interimreport, the investigators foundnosignificantdif-
ference in HRQoL between the 2 treatment arms, except for
itchy skin, which was worse with TTFields.
The finding of worsening itchy skin was not surprising
given the known dermatologic adverse effects of the treat-
ment. In the EF-14 trial, where TTFields was used with con-
current temozolomide shortly after RT, the rate of grade 1 and
2 skin toxic effectswas43%.3 BecauseTTFields therapy is fre-
quently being combined in the real-world setting with other
agents, such as bevacizumab, the resultant skin toxic effects
are not well studied and the incidence may be even higher.
Hence, evaluation and appropriate and rapidmanagement of
skin toxic effects are critical to avoid significant treatment
interruptions—and even discontinuation—to maximize
TTFields therapyadherenceand the resulting survival benefit.
One of the difficulties of this study,7 which is common to
many evaluations of HRQoL, is the low adherence to HRQoL
assessments. Although 91.9% of patients had HRQoL assess-
ments at baseline (before randomization), only 65.8%had as-
sessments at 3 months and 41.7% at 12 months of follow-up.
However, the authors performed sensitivity analyses with
mixed-model analyses to account formissingdata,whichcon-
firm their findings.
It is comforting to learn that theburdenof carrying thede-
vicewas not detrimental to patients’ physical, social, or emo-
tional functioning; however, overall it is important to remem-
ber that the trial participants were a highly selective group of
patients. These individuals elected to takepart in the trial, and
thus represent a group of patients who are already open to
wearing a device on their scalp daily for an indefinite time. In
ourexperience, therearemanysocial andcultural reasons that
patients have for declining TTFields despite the data of im-
proved survival. Many do not want the physical and visual
cues that may remind them of their life-altering, life-limiting
diagnosis. This factor may echo studies finding that patients
with breast cancer rate alopecia as one of the most distress-
ing treatment-related adverse effects because it can result
in anxiety, depression, negative body image, lowered self-
esteem, and reduced sense of well-being.8
With societal changes and the greater acceptability of
wearable devices, ranging from fitness trackers to assistive
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